Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: Safety, tolerability, and pharmacokinetics in healthy subjects

Orphanet Journal of Rare Diseases

Volumn 12, Issue 1, 2017, Pages

  Guerard N ^a   Morand, O ^a   Dingemanse, J ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Lucerastat; Pharmacokinetics; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LUCERASTAT; PLACEBO; 1 DEOXYNOJIRIMYCIN; CARBOHYDRATE; MIGALASTAT;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FLU LIKE SYNDROME; GLYCOLIPID STORAGE DISORDER; HEADACHE; HUMAN; HUMAN EXPERIMENT; LYMPHADENITIS; MALE; MAXIMUM PLASMA CONCENTRATION; NECK PAIN; NORMAL HUMAN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STORAGE DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; HALF LIFE TIME; MIDDLE AGED; YOUNG ADULT;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; AREA UNDER CURVE; CARBOHYDRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 85009493971     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-017-0565-9     Document Type: Article

References (21)

1. Klein AD, Futerman AH. Lysosomal storage disorders: old diseases, present and future challenges. Pediatr Endocrinol Rev. 2013;11 Suppl 1:59-63.
2. Schulze H, Sandhoff K. Lysosomal lipid storage diseases. Cold Spring Harbor perspectives in biology. 2011;3 (6) doi: 10.1101/cshperspect.a004804
3. Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study G. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102. doi: 10.1186/1750-1172-7-102.
4. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27(6):757-66. doi: 10.1023/B:BOLI.0000045756.54006.17.
5. Lachmann RH, te Vruchte D, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L, Dwek RA, Butters TD, Cox TM, Platt FM. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis. 2004;16(3):654-8. doi: 10.1016/j.nbd.2004.05.002.
6. Scott LJ. Eliglustat: a review in Gaucher disease type 1. Drugs. 2015;75(14):1669-78. doi: 10.1007/s40265-015-0468-9.
7. Butters TD, van den Broek LAGM, Fleet GWJ, Krulle TM, Wormald MR, Dwek RA, Platt FM. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron Asymmetry. 2000;11(1):113-24. http://dx.doi.org/10.1016/S0957-4166(99)00468-1.
8. Ridley CM, Thur KE, Shanahan J, Thillaiappan NB, Shen A, Uhl K, Walden CM, Rahim AA, Waddington SN, Platt FM, van der Spoel AC. beta-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem. 2013;288(36):26052-66. doi: 10.1074/jbc.M113.463562.
9. Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem. 1994;269(43):27108-14.
10. Andersson U, Butters TD, Dwek RA, Platt FM. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000;59(7):821-9.
11. Mellor HR, Platt FM, Dwek RA, Butters TD. Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. Biochem J. 2003;374(Pt 2):307-14. doi: 10.1042/BJ20030348.
12. Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, Platt FM. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis. 2004;16(3):506-15. doi: 10.1016/j.nbd.2004.04.012.
13. Baek RC, Kasperzyk JL, Platt FM, Seyfried TN. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int. 2008;52(6):1125-33. doi: 10.1016/j.neuint.2007.12.001.
14. Administration UFaD. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002.
15. Remenova T, Morand O, Amato D, Chadha-Boreham H, Tsurutani S, Marquardt T. A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat. Orphanet J Rare Dis. 2015;10:81. doi: 10.1186/s13023-015-0297-7.
16. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995;29(3):1039-48. doi: 10.1177/009286159502900324.
17. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278-83.
18. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-79. doi: 10.1503/cmaj.1040752.
19. Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol. 1999;48(1):19-23. doi: 10.1046/j.1365-2125.1999.00952.x.
20. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37(3):298-314. doi: 10.1080/00498250601094543.
21. Guérard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford R, Dingemanse J, Wanner C. Lucerastat, an iminosugar for substrate reduction therapy: safety, tolerability, pharmacodynamics, and pharmacokinetics in adult subjects with Fabry disease. WORLDSymposium, Abstract number 17-A-247. 2017.